vs
Side-by-side financial comparison of AMBARELLA INC (AMBA) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
Nutex Health, Inc. is the larger business by last-quarter revenue ($151.7M vs $108.5M, roughly 1.4× AMBARELLA INC). Nutex Health, Inc. runs the higher net margin — 7.8% vs -13.9%, a 21.7% gap on every dollar of revenue. On growth, AMBARELLA INC posted the faster year-over-year revenue change (31.2% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $31.4M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 45.0%).
Ambarella, Inc. is an American fabless semiconductor design company, focusing on low-power, high-definition (HD) and Ultra HD video compression, image processing, and computer vision processors. Ambarella's products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver and in-cabin monitoring, autonomous driving, and robotics applications. Ambarella's system on chips ...
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
AMBA vs NUTX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $108.5M | $151.7M |
| Net Profit | $-15.1M | $11.8M |
| Gross Margin | 59.6% | 30.4% |
| Operating Margin | -15.0% | 20.4% |
| Net Margin | -13.9% | 7.8% |
| Revenue YoY | 31.2% | -41.1% |
| Net Profit YoY | 37.2% | -80.8% |
| EPS (diluted) | $-0.35 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $108.5M | $151.7M | ||
| Q3 25 | $95.5M | $267.8M | ||
| Q2 25 | $85.9M | $244.0M | ||
| Q1 25 | $84.0M | $211.8M | ||
| Q4 24 | $82.7M | $257.6M | ||
| Q3 24 | $63.7M | $78.8M | ||
| Q2 24 | $54.5M | $76.1M | ||
| Q1 24 | $51.6M | $67.5M |
| Q4 25 | $-15.1M | $11.8M | ||
| Q3 25 | $-20.0M | $55.4M | ||
| Q2 25 | $-24.3M | $-17.7M | ||
| Q1 25 | $-20.2M | $21.2M | ||
| Q4 24 | $-24.1M | $61.6M | ||
| Q3 24 | $-34.9M | $-8.8M | ||
| Q2 24 | $-37.9M | $-364.0K | ||
| Q1 24 | $-60.6M | $-364.0K |
| Q4 25 | 59.6% | 30.4% | ||
| Q3 25 | 58.9% | 57.8% | ||
| Q2 25 | 60.0% | 51.2% | ||
| Q1 25 | 60.0% | 55.9% | ||
| Q4 24 | 60.6% | 55.0% | ||
| Q3 24 | 60.8% | 27.8% | ||
| Q2 24 | 60.9% | 29.7% | ||
| Q1 24 | 59.8% | 15.1% |
| Q4 25 | -15.0% | 20.4% | ||
| Q3 25 | -23.0% | 48.7% | ||
| Q2 25 | -30.1% | 13.8% | ||
| Q1 25 | -30.2% | 38.1% | ||
| Q4 24 | -30.9% | 44.4% | ||
| Q3 24 | -56.9% | 12.3% | ||
| Q2 24 | -72.4% | 7.0% | ||
| Q1 24 | -80.8% | 2.1% |
| Q4 25 | -13.9% | 7.8% | ||
| Q3 25 | -20.9% | 20.7% | ||
| Q2 25 | -28.3% | -7.3% | ||
| Q1 25 | -24.1% | 10.0% | ||
| Q4 24 | -29.1% | 23.9% | ||
| Q3 24 | -54.8% | -11.2% | ||
| Q2 24 | -69.6% | -0.5% | ||
| Q1 24 | -117.4% | -0.5% |
| Q4 25 | $-0.35 | $2.34 | ||
| Q3 25 | $-0.47 | $7.76 | ||
| Q2 25 | $-0.58 | $-2.95 | ||
| Q1 25 | $-0.48 | $3.33 | ||
| Q4 24 | $-0.58 | $11.56 | ||
| Q3 24 | $-0.85 | $-1.72 | ||
| Q2 24 | $-0.93 | $-0.07 | ||
| Q1 24 | $-1.51 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $174.1M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $590.1M | $329.4M |
| Total Assets | $751.9M | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $174.1M | $185.6M | ||
| Q3 25 | $142.7M | $166.0M | ||
| Q2 25 | $141.3M | $96.7M | ||
| Q1 25 | $144.6M | $84.7M | ||
| Q4 24 | $127.1M | $40.6M | ||
| Q3 24 | $153.9M | $46.9M | ||
| Q2 24 | $131.8M | $40.8M | ||
| Q1 24 | $144.9M | $30.0M |
| Q4 25 | $590.1M | $329.4M | ||
| Q3 25 | $576.5M | $317.2M | ||
| Q2 25 | $572.7M | $235.3M | ||
| Q1 25 | $561.4M | $176.9M | ||
| Q4 24 | $554.3M | $132.4M | ||
| Q3 24 | $547.6M | $60.4M | ||
| Q2 24 | $555.4M | $62.7M | ||
| Q1 24 | $559.9M | $63.0M |
| Q4 25 | $751.9M | $918.5M | ||
| Q3 25 | $706.4M | $964.5M | ||
| Q2 25 | $701.9M | $841.0M | ||
| Q1 25 | $689.0M | $761.9M | ||
| Q4 24 | $670.8M | $655.3M | ||
| Q3 24 | $650.3M | $438.5M | ||
| Q2 24 | $638.7M | $422.4M | ||
| Q1 24 | $657.7M | $404.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $34.3M | $70.4M |
| Free Cash FlowOCF − Capex | $31.4M | $69.0M |
| FCF MarginFCF / Revenue | 29.0% | 45.5% |
| Capex IntensityCapex / Revenue | 2.7% | 0.9% |
| Cash ConversionOCF / Net Profit | — | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | $64.3M | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.3M | $70.4M | ||
| Q3 25 | $5.5M | $99.5M | ||
| Q2 25 | $14.8M | $27.3M | ||
| Q1 25 | $25.4M | $51.0M | ||
| Q4 24 | $6.6M | $54.0K | ||
| Q3 24 | $16.7M | $6.8M | ||
| Q2 24 | $-15.0M | $13.3M | ||
| Q1 24 | $-4.0M | $3.1M |
| Q4 25 | $31.4M | $69.0M | ||
| Q3 25 | $1.4M | $99.2M | ||
| Q2 25 | $10.2M | $26.5M | ||
| Q1 25 | $21.2M | $50.9M | ||
| Q4 24 | $4.1M | $-341.0K | ||
| Q3 24 | $14.2M | $6.2M | ||
| Q2 24 | $-16.1M | $12.7M | ||
| Q1 24 | $-6.0M | $2.3M |
| Q4 25 | 29.0% | 45.5% | ||
| Q3 25 | 1.4% | 37.0% | ||
| Q2 25 | 11.9% | 10.9% | ||
| Q1 25 | 25.3% | 24.0% | ||
| Q4 24 | 5.0% | -0.1% | ||
| Q3 24 | 22.2% | 7.8% | ||
| Q2 24 | -29.5% | 16.7% | ||
| Q1 24 | -11.6% | 3.4% |
| Q4 25 | 2.7% | 0.9% | ||
| Q3 25 | 4.3% | 0.1% | ||
| Q2 25 | 5.3% | 0.3% | ||
| Q1 25 | 5.0% | 0.0% | ||
| Q4 24 | 3.0% | 0.2% | ||
| Q3 24 | 4.0% | 0.8% | ||
| Q2 24 | 2.1% | 0.7% | ||
| Q1 24 | 3.7% | 1.1% |
| Q4 25 | — | 5.95× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.40× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMBA
| TW | $76.0M | 70% |
| Asia Pacific Other Than Taiwan | $20.2M | 19% |
| North America Other Than United States | $7.4M | 7% |
| Other | $5.0M | 5% |
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
